Generative AI drug creation company Absci Corporation (Nasdaq:ABSI) and Almirall S.A. (BME:ALM), a biopharmaceutical company focused on medical dermatology, said on Tuesday that they are joining forces in a groundbreaking drug discovery partnership.
The collaboration, marking Almirall's first de novo AI drug venture, aims to develop and commercialise AI-designed therapeutics targeting chronic dermatological diseases.
This strategic alliance leverages Absci's Integrated Drug Creation platform and Almirall's dermatological expertise to advance the development of life-changing medicines for patients. The partnership underscores Absci's recent achievement in designing and validating de novo therapeutic antibodies using its 'zero-shot' generative AI technology.
Under the agreement, Absci will apply its de novo generative AI to create and commercialise therapeutic candidates for two dermatological targets. In addition to product royalties, Absci stands to receive up to approximately USD650m in upfront fees, R&D and post-approval milestone payments across the two programmes, contingent on successful milestones.
Absci's founder and CEO, Sean McClain, highlighted the transformative potential of this collaboration in dermatologic drug development, foreseeing significant advancements in using AI for treating chronic inflammatory diseases more broadly. The partnership, addressing critical medical needs, aligns with Absci's commitment to creating improved biologics for a wide range of diseases impacting millions worldwide.
Nektar Therapeutics showcases rezpegaldesleukin at EADV 2024
Priovant Therapeutics enrols first patients in brepocitinib CLARITY study
Kine Sciences reports first patient dosed in KINE-101 Phase 1b/2a clinical study
Johnson & Johnson receives approval from FDA for TREMFYA (guselkumab)
Pfizer names new Regional President for Middle East, Russia and Africa
GSK's Nucala approved in Japan for chronic rhinosinusitis with nasal polyps
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation
Lipella launches OLP Patient Registry to advance research
Talphera enrols first subject in NEPHRO CRRT study
Pfizer reports positive results for ABRYSVO RSV vaccine in immunocompromised adults
Cantargia reports positive CAN10 trial data
Quoin Pharmaceuticals to study QRX003 for Peeling Skin Syndrome
Dragonfly Therapeutics names new chief financial officer
Formosa Pharmaceuticals secures exclusive Canadian licensing deal with Apotex
Bio-Techne invests in Spear Bio to boost ultra-sensitive immunoassay development